Holding(s) in Company

Haleon PLC
10 October 2023
 

Icon Description automatically generated

10 October 2023

HALEON PLC 

("Haleon" or "the Company")  

 

TR-1: Standard form for notification of major holdings  

 

 

1. Issuer Details

ISIN

GB00BMX86B70

Issuer Name

HALEON PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

GSK plc

City of registered office (if applicable)

BRENTFORD

Country of registered office (if applicable)

United Kingdom

Name

City of registered office

Country of registered office

GSK GP 1 Limited

Edinburgh

Scotland

GSK LP Limited

London

England

4. Details of the shareholder

Name

City of registered office

Country of registered office

Vidacos Nominees Limited

London

England

5. Date on which the threshold was crossed or reached

06-Oct-2023

6. Date on which Issuer notified

09-Oct-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

7.420000

0.000000

7.420000

685320110

Position of previous notification (if applicable)

10.350000

0.000000

10.350000


8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BMX86B70

0

685320110

0.000000

7.420000

Sub Total 8.A

685320110

7.420000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 





Sub Total 8.B1




8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 






Sub Total 8.B2




9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

GSK plc (Chain 1)


2.850000


2.850000%

GSK plc (Chain 1)

GlaxoSmithKline Holdings Limited (Chain 1)

2.850000


2.850000%

GSK plc (Chain 1)

GlaxoSmithKline Finance plc (Chain 1)

2.850000


2.850000%

GSK plc (Chain 1)

Glaxo Group Limited (Chain 1)

2.850000


2.850000%

GSK plc (Chain 2)


4.580000


4.580000%

GSK plc (Chain 2)

GSK LP Limited (Chain 2)

4.580000


4.580000%

GSK plc (Chain 2)

GSK GP 1 Limited (Chain 2)

4.580000


4.580000%

GSK plc (Chain 2)

GSK (No. 1) Scottish Limited Partnership (Chain 2)

4.580000


4.580000%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

GSK plc is making this notification on behalf of itself and on behalf of GSK LP Limited and GSK GP 1 Limited.

This notification relates to the sale by GSK (No.1) Scottish Limited Partnership, GSK (No.2) Scottish Limited Partnership and GSK (No.3) Scottish Limited Partnership (entities that are indirectly wholly-owned by GSK plc) of (in the case of GSK (No.1) Scottish Limited Partnership) a portion of its interest and (in the case of GSK (No.2) Scottish Limited Partnership and GSK (No.3) Scottish Limited Partnership) all of their respective interests in Haleon plc.

GSK GP 1 Limited is the sole general partner of GSK (No.1) Scottish Limited Partnership and GSK (No.2) Scottish Limited Partnership. GSK LP Limited is the sole limited partner of GSK (No.1) Scottish Limited Partnership, GSK (No.2) Scottish Limited Partnership and GSK (No.3) Scottish Limited Partnership.

Glaxo Group Limited and GSK (No.1) Scottish Limited Partnership hold their shares in Haleon plc via a custodian, Vidacos Nominees Limited, which holds the legal title to those shares on their behalf pursuant to a custody arrangement.

12. Date of Completion

09-Oct-2023

13. Place Of Completion

London, England

 

Amanda Mellor, Company Secretary

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings